Literature DB >> 14993931

The role of cathepsin K in normal bone resorption.

Bruce R Troen1.   

Abstract

Cathepsin K is essential for normal bone resorption; humans lacking cathepsin K exhibit pycnodysostosis, which is characterized by short stature and osteosclerosis. Cathepsin K knockout mice develop osteopetrosis and display features characteristic of pycnodysostosis, and osteoclasts isolated from these mice exhibit impaired bone resorption in vitro. Bone resorption depends upon the synthesis of cathepsin K by osteoclasts and its secretion into the extracellular compartment at the attachment site between osteoclasts and the bone surface, wherein the organic matrix is subsequently degraded by cathepsin K. Factors that directly modulate osteoclastic bone resorption, including cytokines (RANK ligand, tumor necrosis factor-alpha and interferon gamma), hormones (retinoic acid and estrogen) and nuclear transcriptional factors (c-jun and Mitf) also regulate cathepsin K gene expression. Osteoporosis is one of the leading causes of morbidity in the elderly and is characterized by a persistent excess of osteoclastic bone resorption. Therefore, cathepsin K is an attractive target for therapeutic intervention to prevent and ameliorate the significant deleterious impact of osteoporosis. (c) 2004 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14993931     DOI: 10.1358/dnp.2004.17.1.829022

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  40 in total

Review 1.  Paget disease of bone.

Authors:  G David Roodman; Jolene J Windle
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

2.  Aging and bone loss: new insights for the clinician.

Authors:  Oddom Demontiero; Christopher Vidal; Gustavo Duque
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-04       Impact factor: 5.346

3.  Cathepsin B inhibition limits bone metastasis in breast cancer.

Authors:  Nimali P Withana; Galia Blum; Mansoureh Sameni; Clare Slaney; Arulselvi Anbalagan; Mary B Olive; Bradley N Bidwell; Laura Edgington; Ling Wang; Kamiar Moin; Bonnie F Sloane; Robin L Anderson; Matthew S Bogyo; Belinda S Parker
Journal:  Cancer Res       Date:  2012-01-19       Impact factor: 12.701

4.  A small molecule, odanacatib, inhibits inflammation and bone loss caused by endodontic disease.

Authors:  Liang Hao; Wei Chen; Matthew McConnell; Zheng Zhu; Sheng Li; Michael Reddy; Paul D Eleazer; Min Wang; Yi-Ping Li
Journal:  Infect Immun       Date:  2015-01-12       Impact factor: 3.441

Review 5.  Human Genetics of Sclerosing Bone Disorders.

Authors:  Raphaël De Ridder; Eveline Boudin; Geert Mortier; Wim Van Hul
Journal:  Curr Osteoporos Rep       Date:  2018-06       Impact factor: 5.096

6.  Transcription factor MITF regulates cardiac growth and hypertrophy.

Authors:  Sagi Tshori; Dan Gilon; Ronen Beeri; Hovav Nechushtan; Dmitry Kaluzhny; Eli Pikarsky; Ehud Razin
Journal:  J Clin Invest       Date:  2006-09-21       Impact factor: 14.808

Review 7.  Osteogenesis imperfecta and therapeutics.

Authors:  Roy Morello
Journal:  Matrix Biol       Date:  2018-03-11       Impact factor: 11.583

8.  In vitro method for the screening and monitoring of estrogen-deficiency osteoporosis by targeting peripheral circulating monocytes.

Authors:  Francesca Salamanna; Melania Maglio; Gianluca Giavaresi; Stefania Pagani; Roberto Giardino; Milena Fini
Journal:  Age (Dordr)       Date:  2015-08-07

9.  The Actin-Binding Protein Cofilin and Its Interaction With Cortactin Are Required for Podosome Patterning in Osteoclasts and Bone Resorption In Vivo and In Vitro.

Authors:  Detina Zalli; Lynn Neff; Kenichi Nagano; Nah Young Shin; Walter Witke; Francesca Gori; Roland Baron
Journal:  J Bone Miner Res       Date:  2016-05-27       Impact factor: 6.741

10.  The imbalance between osteoprotegerin and cathepsin K in the serum of patients with longstanding rheumatoid arthritis.

Authors:  Martin Skoumal; Günther Haberhauer; Gernot Kolarz; Gerhard Hawa; Wolfgang Woloszczuk; Anton Klingler; Franz Varga; Klaus Klaushofer
Journal:  Rheumatol Int       Date:  2007-12-13       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.